权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Purchase of a Q Exactive HF mass spectrometer system for metabolomics

购买用于代谢组学的 Q Exactive HF 质谱仪系统

基本信息

批准号：
9274622
负责人：
DAVID W. SPEICHER
金额：
$ 60万
依托单位：
WISTAR INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-04-15 至 2018-04-14
项目状态：
已结题

项目摘要

PROJECT SUMMARY / ABSTRACT This is a proposal to acquire a Thermo Q Exactive HF mass spectrometer and a conventional flow UPLC for a range of metabolomics assays including untargeted (global) metabolite comparisons, flux analyses, and lipidomics profiling (untargeted and targeted). This instrument is needed to support 8 major users and 2 other users at the Wistar Institute to conduct metabolism and lipidome studies involving 22 NIH grants. Eight of these users have multiple NIH grants that will benefit from the requested mass spectrometer system. One of the other users is Dr. Zachary Schug who does not yet have NIH funding because he recently moved from his postdoctoral position in Scotland to the Wistar Institute. Dr. Schug is a critical contributor to this proposal because he has in-depth expertise in all of the analytical approaches that will be used. It is estimated that this user group will initially require nearly all available time on the requested instrument. However, we expect to improve throughput with experience and anticipate that in future years the number of users will grow substantially, thereby ensuring that this instrument will continue to be heavily utilized. Acquisition of this instrument and expansion of our metabolomics capacity is part of a strong institutional commitment driven by the expanding role of metabolism in multiple aspects of cancer biology and other human diseases, coupled with very limited and inadequate access to these technologies from external sources. As a result, metabolism studies at the Wistar Institute have sometimes not been pursued due to logistical barriers and studies that were pursued sometimes suffered from the lack of adequate consultative expertise to ensure optimal experiment design. The requested system will be housed in the Wistar Institute Proteomics and Metabolomics Core Facility under the supervision of the Facility’s Scientific Director, Dr. David Speicher. Day-to-day maintenance and operation of the instrument will be handled by Dr. Hamid Baniasadi, who trained in Dan Raftery’s lab and has more than 8 years of experience with developing and using metabolomics assays. In addition, Dr. Zachary Schug, who is a recently recruited assistant professor from Eyal Gottlieb’s lab, will provide expert consultative advice and will train and educate users through training workshops, a metabolomics journal club, and individual consultation as needed. The Wistar Institute’s CEO and Cancer Center Director confirms the Institute’s very strong commitment to implementing and maintaining state-of-the-art metabolomics capacities. Wistar has already invested more than $1.6M in metabolomics expertise and capacities. Specific to this grant, the Institute is committed to: 1) providing the $66,571 balance of the purchase price above the SIG cap, 2) covering any costs associated with instrument installation, 3) ensuring support is available for expert operators and instrument maintenance throughout its useful lifetime, and 4) ensuring that NIH funded investigators have primary access to the instrument.

项目摘要/摘要